Also trades as: FRX.TO (TSX) · $vol 0M
FENC NASDAQ
Fennec Pharmaceuticals Inc.
1W: +38.8%
1M: +45.0%
3M: +8.8%
YTD: +27.1%
1Y: +42.7%
3Y: +30.0%
5Y: +63.2%
$9.79
+0.03 (+0.31%)
Weekly Expected Move ±19.5%
$6
$8
$10
$12
$14
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$278.9M
52W Range5.65-10.27
Volume288,273
Avg Volume223,113
Beta0.91
Dividend—
Analyst Ratings
Company Info
CEOJeffrey S. Hackman
Employees32
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-15
Websitefennecpharma.com
68 TW Alexander Drive
Research Triangle Park, NC 27709
US
Research Triangle Park, NC 27709
US
919 636 4530
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Latest News
Fennec (FENC) Q1 2026 Earnings Call Transcript
Do Options Traders Know Something About Adherex Technologies Stock We Don't?
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RALLIS CHRIS A | M-Exempt | 14,344 | $2.44 | 2026-05-11 |
| RALLIS CHRIS A | M-Exempt | 14,344 | $2.44 | 2026-05-11 |
| RALLIS CHRIS A | S-Sale | 8,346 | $7.04 | 2026-05-11 |
| Raykov Rosty | M-Exempt | 15,598 | $2.45 | 2026-05-01 |
| Raykov Rosty | M-Exempt | 15,598 | $2.45 | 2026-05-01 |